Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Awareness Related to Target Disorders Among the Patient Population
4.2.2 Rising Stress Levels and Changing Dynamics
4.2.3 Presence of Potential Clinical Pipeline Candidates
4.3 Market Restraints
4.3.1 Lower Diagnosis Rate and Low Treatment Rate
4.3.2 Side Effects of Sleep Disorders Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 Benzodiazepines
5.1.2 Nonbenzodiazepines
5.1.3 Antidepressants
5.1.4 Orexin Antagonists
5.1.5 Melatonin Antagonists
5.1.6 Other Drug Types
5.2 By Application
5.2.1 Insomnia
5.2.2 Sleep Apnea
5.2.3 Narcolepsy
5.2.4 Circadian Disorders
5.2.5 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Rest of the World


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Dr Reddy’s Laboratory
6.1.2 Merck & Co
6.1.3 Mylan NV
6.1.4 Pfizer
6.1.5 Sanofi S.A
6.1.6 Takeda Pharmaceuticals USA Inc.
6.1.7 Teva Pharmaceuticals USA Inc.
6.1.8 Transcept Pharmaceuticals
6.1.9 Vanda Pharmaceuticals Inc.
6.1.10 Zydus Cadila


7 MARKET OPPORTUNITIES AND FUTURE TRENDS